{"id":"W2115790682","doi":"10.1056/nejmoa071834","title":"Cetuximab for the Treatment of Colorectal Cancer","year":2007,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1806,"is_retracted":false,"has_abstract":true,"ca_institutions":"Lakeridge Health; Sunnybrook Health Science Centre; Queen's University; Ottawa Hospital; St. Boniface Hospital; University of Ottawa","funders":"","keywords":"Cetuximab; Medicine; Irinotecan; Hazard ratio; Internal medicine; Colorectal cancer; Oxaliplatin; Oncology; Confidence interval; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03249577843555444,"score_gpt":0.3453493300105736,"score_spread":0.3128535515750191,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}